<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734885_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151009</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>US-ELI_LILLY_AND_COMPANY-US201212008403</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130123</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121228</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130116</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-ELI_LILLY_AND_COMPANY-US201212008403</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>US-ELI_LILLY_AND_COMPANY-US201210001015</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reportertitle>Ms.</reportertitle>
			<reportergivename>Jewel</reportergivename>
			<reporterfamilyname>Printy</reporterfamilyname>
			<reporterstreet>805 West Kannal Avenue
Apartment 20</reporterstreet>
			<reportercity>Rensselaer</reportercity>
			<reporterstate>IN</reporterstate>
			<reporterpostcode>47978</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>Novo Nordisk</reporterfamilyname>
			<reporterstreet>100 College Road West</reporterstreet>
			<reportercity>Princeton</reportercity>
			<reporterstate>NJ</reporterstate>
			<reporterpostcode>08540</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JP</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19501106</patientbirthdate>
			<patientsex>2</patientsex>
			<reaction>
				<primarysourcereaction>passed out due to high blood sugar</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hyperglycemic unconsciousness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hyperglycaemic unconsciousness</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201008</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Blood glucose</testname>
				<testresult>412</testresult>
				<testunit>mg/dl</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugdosagetext>UNK, unknown</drugdosagetext>
				<drugdosageform>Injection</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug>1</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemic unconsciousness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemic unconsciousness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LEVEMIR</medicinalproduct>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>UNK, unknown</drugdosagetext>
				<drugdosageform>Injection</drugdosageform>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN DETEMIR</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a consumer and forwarded by a manufacturer, concerns a 59 year old female patient of unknown origin. Additional information was received from the consumer.

Medical history was not reported. Concomitant medications included insulin detemir via vial. 

The patient received insulin lispro (Humalog) for Type 2 diabetes mellitus beginning on an unknown date. Dose and frequency was not reported. In Aug2010, an unknown time after initiation of insulin lispro, the patient passed out for two hours due to high blood sugar. This event was considered serious by the company due to medical significance. The patient awoke two hours later with a blood sugar of 412 mg/dl. The patient drank a lot of water and recovered. It was reported that the patient did not seek treatment from her physician and did not require hospitalization. No further information was provided and corrective treatment was not reported. The outcome of the event was recovered; the patient is doing much better and is eating more vegetables, apples, leafy vegetables and everything. On an unknown date therapy with insulin lispro was discontinued.

Additional Case(s) for Same Patient: US201210001015

Update 22-Jan-2013: Information reported on 01-Oct-2012 to non-serious events was previously captured in case US201210001015. Follow up information was received from consumer on 16-Jan-2013. Added date of birth and age. Added indication for suspect product. Updated action taken and updated dechallenge. Added formulation vial for concomitant medication. Updated narrative.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
